Printer Friendly

King Pharmaceuticals announces FDA approval of new Bicillin[R] manufacturing facility.

King Pharmaceuticals, Inc. recently announced that the FDA has approved the company's new state-of-the-art manufacturing and production facility in Rochester, Michigan for its Bicillin[R] product line. Bicillin[R] L-A (penicillin G benzathine injectable suspension) is the first product available from this facility.

The recent Sexually Transmitted Diseases Treatment Guidelines issued in 2006 by the Centers for Disease Control and Prevention (CDC) recommends penicillin G as the preferred treatment of all stages of syphilis. Bicillin[R] L-A, administered via deep intramuscular injection, has been used effectively for more than 60 years to cure syphilis and prevent sexual transmission.

"This modern facility demonstrates King's commitment to the continued importance of treating and controlling infectious diseases," stated Eric J. Bruce, Chief Technical Operations Officer, King Pharmaceuticals, Inc. "With syphilis on the rise in major cities across the U.S., the new facility expands our production capacity to ensure continued availability of Bicillin[R] L-A to healthcare providers and patients."

To streamline the ease and use of Bicillin[R] L-A, King is now using the Becton Dickinson Hypack Luer-Lok syringe system with the Eclipse safety-cover needle. The Bicillin[R] L-A package carton contains five prefilled syringes per thermoform tray, two trays per carton and 10 needles individually sterilized and packaged.

Bicillin[R] L-A is available in 1 mL Pediatric (600,000 units), 2mL (1,200,000 units) and 4mL (2,400,000 units). The average dose to treat primary, secondary and latent syphilis is 2,400,000 units in one single dose. Bicillin[R] L-A is also indicated for mild-to-moderate infections of the upper respiratory tract due to susceptible streptococci, including streptococcal pharyngitis, and has been used for prophylaxis to prevent recurrence of rheumatic fever and/or chorea.
COPYRIGHT 2007 Advantage Business Media
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry News
Publication:Pharmaceutical Processing
Date:Mar 1, 2007
Words:285
Previous Article:Nortec announces FDA approval of its generic Inderal-La Licensed to Par Pharmaceutical.
Next Article:PDUFA public forum previews hill debate.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters